Image

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Dec 2021
  • MEA
  • 350 Pages
  • No of Tables: 95
  • No of Figures: 46

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market, By Cell Source  (Skin Cells and Blood Cells), Type (Human IPSCs and Mouse IPSCs), Product (Instruments, Consumables & Kits and Services), Applications (Academic Research, Regenerative Medicine, Cellular Therapy, Toxicology Screening, Drug Discovery and Development, Disease Modelling, Stem Cell Banking, 3D Bio printing and Others), End User (Biotechnology & Pharmaceutical Companies, Research Laboratories, Diagnostic Laboratories and Others), Distribution Channel (Direct Tender and Retail Sales), Country (South Africa, Egypt, Saudi Arabia, U.A.E, Israel and Rest of Middle East And Africa) – Industry Trends & Forecast to 2029.

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) MarketMarket Analysis and Insights: Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market

The Middle East and Africa induced pluripotent stem cells (iPSCs) market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.9% in the forecast period of 2022 to 2029 and is expected to reach USD 27.41 million by 2029. Increasing research activities over stem cell therapies act as driver for the induced pluripotent stem cells (iPSCs) market growth.

The induced pluripotent stem cells are type of cells derived from the adult somatic tissues and reprogrammed with set of genes and factors to gain pluripotent nature. Certain genes and factors are added to attain definite properties of embryonic stem cells. The induced pluripotent cells being nearly identical to cell donor they aid in disease modelling. Retroviruses are commonly used as vectors to reprogram induced pluripotent stem cells. Main applications of induced pluripotent stem cells are in disease modelling, drug discovery and development, toxicity studies and gene therapies. They are widely used in treatments for cardiovascular diseases, diabetes mellitus and various types of cancer. Human induced pluripotent stem cells shows the relevant properties of disease as it carries the specific genotype of the disease, thereby enables novel therapeutic options in patient specific way.

Increasing adoption of stem cell therapy, growing biotechnology sector with better investment and rising prevalence of chronic diseases acts as driver for the induced pluripotent stem cells (iPSCs) market. The other factors which are anticipated to propel the growth of the Middle East and Africa induced pluripotent stem cells (iPSCs) market include the Wide range of clinical application of induced pluripotent stem cells and emerging technological advancements of iPSCs.

However, the factors such as the high cost associated with stem cell therapies, availability of alternatives for tumor treatment are hampering the growth of the Middle East and Africa induced pluripotent stem cells (iPSCs) market. On the other hand, the rising number of pipeline products, increased interest of personalized medicine and surge in healthcare expenditure act as an opportunity for the growth of the Middle East and Africa induced pluripotent stem cells (iPSCs) market. The stringent rules and regulations and Genomic instability of IPSC is the key market challenge faced in the Middle East and Africa induced pluripotent stem cells (iPSCs) market.

The induced pluripotent stem cells (iPSCs) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the induced pluripotent stem cells (iPSCs) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) MarketInduced Pluripotent Stem Cells (iPSCs) Market Scope and Market Size

The induced pluripotent stem cells (iPSCs) market is segmented on basis of cell source, type, product, applications, end users and distribution channel The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Middle East and Africa induced pluripotent stem cells (iPSCs) market is categorized into six notable segments based on the cell source, type, product, applications, end users and distribution channel.

  • On the basis of cell source, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into skin cells and blood cells. In 2022, skin cells segment is expected to dominate the market due to its non-invasive extraction and easy source availability for culturing.
  • On the basis of type, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into human IPSCs and mouse IPSCs. In 2022, human IPSCs segment is expected to dominate the market due to its specificity in any disease modeling studies.
  • On the basis of product, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into instruments, consumables & kits and services. In 2022, consumables & kits segment is expected to dominate the market due to rising cancer cases and stem cell kits being used in diagnosing.
  • On the basis of application, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into academic research, regenerative medicine, cellular therapy, toxicology screening, drug discovery and development, disease modelling, stem cell banking, 3D bioprinting and others. In 2022, drug discovery and development segment is expected to dominate the market as research and development on drug discovery using induced pluripotent stem cells (iPSCs) are widely gaining attention lately.
  • On the basis of end-users, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into biotechnology & pharmaceutical companies, research laboratories, diagnostic laboratories and others. In 2022, biotechnology & pharmaceutical companies segment is expected to dominate the market as the region is receiving government fund in improving biotechnology and Pharma Company’s infrastructure for proper drug development process.
  • On the basis of distribution channel, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into direct tender and retail sales. In 2022, direct tender segment is expected to dominate the market as the products are delivered at fair price.

Induced Pluripotent Stem Cells (iPSCs) Market Country Level Analysis

The induced pluripotent stem cells (iPSCs) market is analyzed and market size information is provided by the country, cell source, type, product, applications, end users and distribution channel as referenced above.

The countries covered in the induced pluripotent stem cells (iPSCs) market report are South Africa, Saudi Arabia, U.A.E., Israel, Egypt and rest of Middle East and Africa.

Human iPSCs segment in South Africa of the region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing usage of stem cell technology. The human iPSCs segment in Saudi Arabia is second dominating the market owing to increasing cases of chronic diseases and high adoption of stem cell sources for better therapies. UAE is third in leading the growth of the market and human iPSCs segment is dominating in this country due to increasing number of biotechnology centers and research activities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Induced Pluripotent Stem Cells (iPSCs) Treatment, is Boosting the Market Growth of Induced Pluripotent Stem Cells (iPSCs) Market.

The induced pluripotent stem cells (iPSCs) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.

Competitive Landscape and Induced Pluripotent Stem Cells (iPSCs) Market Share Analysis

Induced pluripotent stem cells (iPSCs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to induced pluripotent stem cells (iPSCs) market.

The major companies which are dealing in the induced pluripotent stem cells (iPSCs) are Thermo Fisher Scientific Inc., FUJIFILM Corporation, Takara Bio Inc., Lonza., Charles River Laboratories International, Inc., Merck KGaA and among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the induced pluripotent stem cells (iPSCs) market.

For instance,

  • In February 2021, Thermo Fisher Scientific Inc. announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company’s footprints in Middle East and Africa market and leading to upsurge company’s growth in the coming years.
  • In June 2020, the LumaCyte collaborated with Catalent who are the Middle East and Africa provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. This collaboration aided in expanding the company’s stem cell technology product Radiance and its application.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company footprints in the veterinary infusion pumps market which also provides the benefit for organization’s profit growth.


SKU-

TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.

TABLE 2 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA HUMAN IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA MOUSE IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA SERVICES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA DRUG DISCOVERY AND DEVELOPMENT IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA ACADEMIC RESEARCH IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA DISEASE MODELLING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA CELLULAR THERAPY IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA REGENERATIVE MEDICINE IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA TOXICOLOGY SCREENING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA STEM CELL BANKING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA 3D BIOPRINTING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA RESEARCH LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA DIAGNOSTIC LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA DIRECT TENDER IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA RETAIL SALES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 45 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 46 SOUTH AFRICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 47 SOUTH AFRICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 48 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 50 SOUTH AFRICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 51 SOUTH AFRICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 52 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 53 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 54 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 55 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 56 SAUDI ARABIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 57 SAUDI ARABIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 58 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 60 SAUDI ARABIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 61 SAUDI ARABIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 62 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 63 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 65 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 66 UAE SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 67 UAE BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 68 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 70 UAE INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 71 UAE CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 72 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 74 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 75 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 76 EGYPT SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 77 EGYPT BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 78 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 80 EGYPT INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 81 EGYPT CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 82 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 83 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 84 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 85 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 86 ISRAEL SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 87 ISRAEL BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 88 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 89 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 90 ISRAEL INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 91 ISRAEL CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 92 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 93 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 94 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 95 REST OF MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market size will be worth USD 27.41 million by 2029.
The Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market growth rate will be 4.9% by 2029.
The Increasing adoption of stem cell therapy, growing biotechnology sector with better investment and rising prevalence of chronic diseases are the growth drivers of the Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market.
The cell source, type, product, applications, end users and distribution channel are the factors on which the Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market research is based.
The major companies in the Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market are Thermo Fisher Scientific Inc., FUJIFILM Corporation, Takara Bio Inc., Lonza., Charles River Laboratories International, Inc., Merck KGaA.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials